secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2026-05-12T20:17:24+00:00
Accession:  0001193125-26-219500
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Q1 net loss $52.9M; completes First Tracks spin-off, Jemperli royalties up 44%
--------------------------------------------------------------------------------

- Net loss per share $1.84 vs $1.28 YoY; collaboration revenue $25.6M (Jemperli royalties $24.7M, +44%).
- Cash $286.5M at March 31; stock repurchase plan of $100M authorized through Dec 31, 2026.
- Spin-off of First Tracks Bio completed Apr 20; now exclusively manages Jemperli (GSK) and imsidolimab (Vanda) financial collaborations.
- Expects >$390M annualized Jemperli royalties by 2029 at GSK's >$2.7B peak sales; Sagard debt paydown by Q2 2027.
- FDA PDUFA Dec 12, 2026 for imsidolimab in GPP; Chris Murphy appointed CFO, Susannah Gray and Owen Hughes to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/0001193125-26-219500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer